Cajanolactone A, a stilbenoid from Cajanus cajan, inhibits energy intake and lipid synthesis/storage, and promotes energy expenditure in ovariectomized mice

Cajanolactone A, a Stilbenoid From Cajanus canjan (L.) Millsp, Prevents High-Fat Diet-Induced Obesity via Suppressing Energy Intake

“…Orexigenic genes in the hypothalamus not only regulate feeding behavior, but also play roles in regulating adipocyte homeostasis, BAT function and energy metabolism by stimulating the receptors and downstream signaling pathways (Goforth and Myers, 2017;Sellayah et al, 2011;Marsh et al, 2002;Kyrkouli et al, 2006). In our studies under high-fat feeding conditions, the hapothalami of mice with ovaries expressed down-regulated level of NPY and unchanged levels of ORX and Gal in the hypothalamus (Figure 3), on the contrary, the hypothalami of mice subjected to ovariectomy expressed up-regulated levels of ORX and Gal but unchanged level of NPY (Luo et al, 2021). Based on the results that CLA suppressed same genes (ORX, ORXR2, pMCH, and Gal) in the hypothalamus and reduced energy intake in both mice, we suggest that CLA has the prospect to prevent excess accumulation of fat in both premenopausal and postmenopausal women.…”

“…Cajanolactone A (CLA) is a stilbenoid discovered by us from the leaves of Cajanus canjan (L.) Millsp promoting osteoblast differentiation in human bone marrow mesenchymal stem cells (Liu et al, 2019). Recently, CLA has been proven to have potential use in treating postmenopausal obesity by protecting the ovariectomized mice from obesity and liver steatosis (Luo et al, 2020;Luo et al, 2021). Because CLA prevents estrogen deficiency-induced obesity in a non-estrogen-like manner, it is suggested that CLA may also have the potential to prevent dietinduced obesity in premenopausal women.…”